ArticleJournal of molecular recognition : JMR2025
Developing a Modular Platform for the Detection of microRNAs Using Rolling Circle Amplification and Multi-Primed Chain Amplification.
Article in Journal of molecular recognition : JMR, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Developing a Modular Platform for the Detection of microRNAs Using Rolling Circle Amplification and Multi-Primed Chain Amplification.Journal of molecular recognition : JMR · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
MicroRNAs (miRNAs) play critical regulatory roles in diverse biological processes and are key biomarkers in a wide range of physiological and pathological conditions, including cancer. However, their inherently low concentrations in biological samples pose a major challenge for reliable detection and quantification. To overcome this limitation, we developed a fluorescence-based biosensing platform that integrates rolling circle amplification (RCA) and multi-primed chain amplification (MCA) to enhance signal and detection sensitivity. The system is engineered to allow flexible reconfiguration for different miRNA targets by altering probe and primer sequences. In this modular system, miR-i, a miRNA commonly expressed in healthy and cancerous samples, serves as a universal initiator for RCA. Signal amplification was subsequently driven by hybridization with two randomly selected miRNAs (miR-A and miR-D), enabling evaluation of system performance under varied input conditions. Fluorescence emission was measured following the addition of a molecular beacon and subsequent spectrofluorometric analysis. The biosensor exhibited a strong linear correlation between miRNA concentration and fluorescence intensity, achieving a limit of detection (LOD), and limit of quantification (LOQ) below 10 pM in both buffer and human serum. These findings demonstrate the platform's high sensitivity and robustness. Importantly, modular architecture allows for easy reconfiguration to detect a wide array of miRNAs or other non-coding RNAs, positioning this platform as a broadly applicable tool for molecular diagnostics beyond any specific disease context.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.